Citations

Clear

2429 citation(s) found for "Shah, SS".

Transcatheter aortic valve replacement in cancer patients with chest radiation therapy: Risks and outcomes.
Farooq, Saad , Khawar, Muneeb , Ali, Umar , Shah, Syed Abdullah , Khawar, Mirza Muhammad Hadeed , Muhammad, Awon, Saeed, Hannan, Khan, Saba , Qadeer, Abdul , Haider, Mobeen Z. , Hamza, Mohammad, Ali, Umad, Muhammad, Awon, Saeed, Hannan, Kirchoff, Robert W.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e24020 Get It

e24020 Background: Transcatheter aortic valve replacement (TAVR) is a widely adopted treatment for severe aortic stenosis, but outcomes in cancer survivors with prior chest radiation therapy (C-XRT) remain uncertain. This study compares the clinical outcomes of TAVR between patients with a history of C-XRT and those without prior radiation exposure (control group). Methods: Patients with prior chest radiation therapy (C-XRT) were compared to a control group without radiation exposure to evaluate key clinical endpoints. For each endpoint, odds ratios (OR) and 95% confidence intervals (CI) were determined, and heterogeneity was analyzed using the I² statistic. A p-value of <0.05 was considered statistically significant. Results: Nine studies were included in the meta-analysis, encompassing 3083 C-XRT and 8891 control patients. Patients with prior C-XRT showed significantly higher long-term mortality (OR 1.84, 95% CI [1.08, 3.13], p=0.02) compared to controls. Other outcomes, including access-related vascular complications, Acute Kidney Injury, Congestive heart failure, major bleeding, need for pacemaker, short-term mortality, and stroke, did not demonstrate significant differences between the groups. Conclusions: Cancer survivors with prior chest radiation therapy undergoing TAVR may experience higher long-term mortality compared to patients without radiation exposure. However, no significant differences were observed in other major outcomes. These findings suggest that while TAVR is a viable treatment for C-XRT patients, long-term risks require further investigation to optimize patient selection and management strategies. Outcomes. Outcome OR 95% Confidence Interval P value Access related vascular complications 1.12 [0.85, 1.48] 0.43 Acute kidney injury 0.54 [0.20, 1.50] 0.24 Congestive heart failure 1.38 [0.88, 2.17] 0.16 Long term mortality 1.84 [1.08, 3.13] 0.02 Major bleeding 0.96 [0.78, 1.17] 0.67 Need for pacemaker 1.05 [0.88, 1.26] 0.57 Short term mortality 1.66 [0.97, 2.84] 0.06 Stroke 1.25 [0.74, 2.11] 0.39
Impact of active cancer on mortality and complications after TAVR: A systematic review and meta-analysis.
Aiman, Wajeeha , Khawar, Muneeb , Qadeer, Abdul , Ali, Umar , Khawar, Mirza Muhammad Hadeed , Saeed, Hannan, Tayyab, Muhammad , Shah, Syed Abdullah , Ali, Muhammad Ashar , Khan, Saba , Haider, Mobeen Z. , Ali, Umad, Saeed, Hannan, Tayyab, Muhammad, Kirchoff, Robert W.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e24024 Get It

e24024 Background: Patients with active cancer undergoing trans catheter aortic valvular replacement (TAVR) face a higher risk of adverse outcomes due to the interplay between cancer and cardiovascular disease. Although TAVR is increasingly used in high-risk populations, data on outcomes for these patients remain limited. This systematic review and meta-analysis aim to evaluate the clinical outcomes associated with TAVR in patients with active cancer compared to non-cancer controls, providing insights to inform clinical decision-making in this unique group. Methods: A systematic search of major databases (PubMed, Embase, OVID, Web of Science, Scopus) was conducted to identify studies comparing clinical outcomes of TAVR between patients with active cancer and those without cancer. Key outcomes included measures of mortality, procedural complications, and post-procedure adverse events. The Mantel-Haenszel method was used for pooled analysis, applying random-effects or fixed-effects modeling based on heterogeneity assessed by Higgins I². Statistical significance was set at a p-value < 0.05. Results: Twelve studies involving 5,73,192 patients (67,684 active cancer, 505508 control) were included. Patients with active cancer undergoing TAVR have significantly higher risks of short-term mortality (OR 1.31, 95% CI [1.15, 1.49], p < 0.0001), long-term mortality (OR 2.24, 95% CI [1.85, 2.70], p < 0.0001), and major bleeding complications (OR 1.80, 95% CI [1.68, 1.92], p < 0.0001). There were no statistically significant differences in cardiovascular mortality (OR 1.33, 95% CI [0.94, 1.89], p = 0.11), myocardial infarction (OR 1.60, 95% CI [0.82, 3.11], p = 0.17), stroke (OR 0.61, 95% CI [0.28, 1.35], p = 0.22), AKI (OR 0.92, 95% CI [0.49, 1.73], p = 0.80), or the need for permanent pacemaker implantation (OR 1.12, 95% CI [0.85, 1.48], p = 0.42). Conclusions: Patients with active cancer undergoing TAVR face significantly higher risks of mortality and major bleeding compared to non-cancer controls. However, the risks of cardiovascular mortality, MI, stroke, AKI, and the need for permanent pacemaker implantation are comparable to those of non-cancer controls. Careful risk assessment and management are crucial for optimizing outcomes in this vulnerable population, and further studies are needed to refine treatment strategies. Odds ratios of all outcomes. Outcomes OR Confidence Interval (95% CI) p-value Short term mortality 1.31 [1.15, 1.49] < 0.0001 Long term mortality 2.24 [1.85, 2.70] < 0.00001 Major bleeding 1.8 [1.68, 1.92] < 0.00001 Cardiovascular mortality 1.33 [0.94, 1.89] 0.11 Myocardial Infarction 1.6 [0.82, 3.11] 0.17 Stroke 0.61 [0.28, 1.35] 0.22 Acute Kidney Injury 0.92 [0.49, 1.73] 0.8 Need for permanent pacemaker implantation 1.12 [0.85, 1.48] 0.42
Anticoagulation Versus Antiplatelets in Spontaneous Cervical Artery Dissection: A Systematic Review and Meta-Analysis
Yaghi, Shadi , Shu, Liqi , Fletcher, Lauren , Fayad, Fayez H. , Shah, Asghar , Herning, Ana, Isho, Noail, Mansour, Perla , Joudi, Kareem , Zaidat, Bashar , Mahmoud, Noor , Khalek, Feras Abdul, Xiao, Han , Ghannam, Malik , Omran, Setareh Salehi , Bakradze, Ekaterina , Khan, Muhib , Henninger, Nils , Field, Thalia S. , Aziz, Yasmin , Mistry, Eva , Furie, Karen L. , Markus, Hugh S. , Mahmoud, Noor A , Goldstein, Eric D , Ghannam, Malik , Siegler, James E , Salehi Omran, Setareh , Bakradze, Ekaterina , Nguyen, Thanh N , Keser, Zafer , Bavarsad Shahripour, Reza , de Havenon, Adam H , Henninger, Nils , Heldner, Mirjam R , Aziz, Yasmin , Mistry, Eva A , Furie, Karen L , Engelter, Stefan T , Markus, Hugh S , Field, Thalia S , Yaghi, Shadi , Xiao, Han , Isho, Noail F., Goldstein, Eric , Siegler, James E. , Nguyen, Thanh N. , Keser, Zafer , Shahripour, Reza Bavarsad , Havenon, Adam de , Heldner, Mirjam R. , Engelter, Stefan T.

Mayo Clinic

Stroke | May 28, 2025 | Volume: 55 | Issue: 7 | Pages: 1776-1786

10.1161/strokeaha.124.047310 | PMID 38847098 Get It

BACKGROUND: It is uncertain whether antiplatelets or anticoagulants are more effective in preventing early recurrent stroke in patients with cervical artery dissection. Following the publication of the observational Antithrombotic for STOP-CAD (Stroke Prevention in Cervical Artery Dissection) study, which has more than doubled available data, we performed an updated systematic review and meta-analysis comparing antiplatelets versus anticoagulation in cervical artery dissection. METHODS: The systematic review was registered in PROSPERO (CRD42023468063). We searched 5 databases using a combination of keywords that encompass different antiplatelets and anticoagulants, as well as cervical artery dissection. We included relevant randomized trials and included observational studies of dissection unrelated to major trauma. Where studies were sufficiently similar, we performed meta-analyses for efficacy (ischemic stroke) and safety (major hemorrhage, symptomatic intracranial hemorrhage, and death) outcomes using relative risks. RESULTS: We identified 11 studies (2 randomized trials and 9 observational studies) that met the inclusion criteria. These included 5039 patients (30% [1512] treated with anticoagulation and 70% [3527]) treated with antiplatelets]. In meta-analysis, anticoagulation was associated with a lower ischemic stroke risk (relative risk, 0.63 [95% CI, 0.43 to 0.94]; P =0.02; I 2 =0%) but higher major bleeding risk (relative risk, 2.25 [95% CI, 1.07 to 4.72]; P =0.03, I 2 =0%). The risks of death and symptomatic intracranial hemorrhage were similar between the 2 treatments. Effect sizes were larger in randomized trials. There are insufficient data on the efficacy and safety of dual antiplatelet therapy or direct oral anticoagulants. CONCLUSIONS: In this study of patients with cervical artery dissection, anticoagulation was superior to antiplatelet therapy in reducing ischemic stroke but carried a higher major bleeding risk. This argues for an individualized therapeutic approach incorporating the net clinical benefit of ischemic stroke reduction and bleeding risks. Large randomized clinical trials are required to clarify optimal antithrombotic strategies for management of cervical artery dissection.
Predictors of post-transplant survival in patients with newly diagnosed acute myeloid leukemia receiving frontline venetoclax and hypomethylating agents.
Johnson, Isla McKerrow , Elbeih, Azeem, Ghosoun, Nour, Al‐Kali, Aref , Begna, Kebede, Elliott, Michelle A. , Mangaonkar, Abhishek A. , Matin, Aasiya , Patnaik, Mrinal M. , Pardanani, Animesh , Litzow, Mark R. , Tefferi, Ayalew, Gangat, Naseema , McCullough, Kristen , Alkhateeb, Hassan B. , Saliba, Antoine N. , Hefazi, Mehrdad , Hogan, William J. , Shah, Meera , Tefferi, Ayalew

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e18523 Get It

e18523 Background: Allogeneic hematopoietic stem cell transplant (AHCT) remains the only curative option for genetically high-risk acute myeloid leukemia (AML). Venetoclax plus hypomethylating agents (Ven+HMA) is approved as frontline treatment in elderly patients with AML ( NEJM 2020; 383); however, less is known on the post-transplant outcomes following such therapy. Methods: Newly diagnosed (ND) AML patients who received Ven+HMA and underwent AHCT at Mayo Clinic from 2019 to 2024 were retrospectively recruited. Patients who required salvage therapy following Ven+HMA were excluded. Post-transplant survival (PTS) and relapse incidence were computed. Results: 55 ND-AML patients (60% male, 49% de novo , median age 69 [38-77]) received Ven+HMA (median cycles 3 [2-11]). ELN 2022 cytogenetic risk at time of diagnosis was non-adverse in 67% of patients, while 33% had adverse karyotype. Common mutations at diagnosis included: K/NRAS (88%), TP53 (26%), RUNX1 (23%), ASXL1 (16%), and IDH1/2 (17%). At the time of AHCT, 98% ( n=54 ) were in CR/CRi or MLFS; ELN cytogenetic risk was non-adverse in 91%, and adverse in 5 (9%) patients. Common mutations included: TP53 (16%), TET2 (18%), SRSF2 (15%), ASXL1 (13%), RUNX1 (18%), and DNMT3A (9%). Donor types included HLA-matched unrelated (75%), haplo-identical (11%), matched related (7%), mismatched unrelated (7%). 58% received fludarabine/melphalan conditioning and 54% GVHD prophylaxis with cyclophosphamide. At a median follow up of 25 months (0.7-68 mo), 20 patients (36%) have died, due to relapse in 10 (18%) cases. 3-year cumulative incidence of non-relapse mortality (NRM) was 17%. Median PTS was not reached (1/2/3-year survival 74%/66%/62%). Univariate analysis identified Karnofsky Performance Score <70% (3 vs. 21 months, p<0.01 ), TP53 (14 vs. 21 months p=0.02 ) and TET2 mutation at time of transplant (11 vs. 21 months , p=0.02 ) as risk factors. Multivariable analysis confirmed the prognostic impact of TP53 (HR 2.8) and TET2 mutations (HR 2.9). Age, adverse karyotype at transplant, and donor type did not impact PTS (p>0.1). 13 patients (24%) experienced post-transplant relapse; 1/2/3-year cumulative incidence of relapse was 10%, 21% and 25%, respectively. ELN-defined adverse karyotype at transplant increased risk of relapse (3 year cumulative incidence 80% vs. 17% for non-adverse , p<0.01 ). Overall, 51% of patients developed GVHD; 54%, 39% and 7% were acute, chronic GVHD and both, respectively. GVHD was protective against relapse (3 year incidence 15% vs. 36% in absence of GVHD [p=0.04]). Conclusions: Ven+HMA frontline treatment is associated with favorable post-transplant outcome in elderly ND-AML (3 year PTS 62%/cumulative incidence of relapse 25%/NRM 17%). TP53 mutation and ELN 2022-defined adverse karyotype at the time of transplant independently predicted PTS and relapse incidence, respectively.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Prognostic factors and outcomes in 68 Mayo Clinic patients.
Andres, Erica, Al‐Kali, Aref , Porrata, Luis F. , Begna, Kebede H. , Foran, James M. , Litzow, Mark R. , Mangaonkar, Abhishek A. , Matin, Aasiya , Patnaik, Mrinal M. , Yi, Cecilia Ysabel Arana, Tefferi, Ayalew , Gangat, Naseema , Csizmar, Clifford M. , McCullough, Kristen , Alkhateeb, Hassan B. , Hefazi, Mehrdad , Hogan, William J. , Murthy, Hemant S. , Saliba, Antoine N. , Shah, Meera

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e18508 Get It

e18508 Background: BPDCN is a rare and aggressive hematologic malignancy. Despite the advent of targeted therapies, median overall survival (mOS) remains <1 year (y) in the absence of stem cell transplant (SCT). This study evaluates clinical and molecular predictors of outcomes in a large cohort of BPDCN patients at a tertiary center. Methods: BPDCN patients seen at Mayo Clinic (AZ, FL, MN) between 2000-2024 were identified retrospectively. Analyses considered parameters at diagnosis. Next generation sequencing (NGS) was performed using a 47-gene assay. Standard statistical methods were used; calculations used R. Results: Among 69 patients, the median age was 70y (range 19-94) with male predominance (83%). At presentation, skin (80%), bone marrow (73%), lymph nodes (52%), spleen (27%), and CNS (12%) were involved; 26% had a concurrent hematologic malignancy. Among 20 cases with NGS, the median number of mutations was 3 (range 0-5), most frequently TET2 (n=16), ASXL1 (n=13), SRSF2 (n=7), and NRAS (n=5). Frontline therapy (Table) yielded a complete response (CR) rate of 63% and overall response rate of 76%. CR rates were similar among regimens, but patients who received an ALL (hyper-CVAD based) regimen (8/13) or tagraxofusp (6/9) were more likely to be bridged to SCT (6/29, p<0.01). After median follow up of 38 months (mo), mOS for all was 15 (95% CI 12-21) mo; 44 (64%) were deceased at last follow up. Among 62 evaluable patients, 20 (32%, median age 60 vs 74y, p<0.01) underwent SCT which improved survival (mOS 51 vs 10 mo, 3y OS 52% vs 5%, p<0.01); mOS was not different between allogeneic (n=17) and autologous (n=3) SCT (54 vs 38 mo, p=0.45). When censored for SCT, the 1y OS for patients receiving an ALL regimen, tagraxofusp, or other regimen was 82%, 67%, and 47%, respectively (p=0.15). In univariate analysis, age ≥50y, lymph node involvement, bone marrow involvement, hemoglobin <10 g/dL, leukocytes (WBC) >11 x10 9 /L, abnormal karyotype, and HCT were significantly associated with OS. In multivariate analysis, WBC >11 x10 9 /L (HR 3.7, p<0.03), abnormal karyotype (HR 5.4, p<0.01), and SCT (HR 0.23, p<0.01) remained significant. Separately, SRSF2 mutation was associated with inferior OS (15 vs 51 mo, p=0.02), but significance was lost when adjusted for age, abnormal karyotype, and SCT. Conclusions: Newly-diagnosed BPDCN patients treated with an ALL regimen or tagraxofusp followed by SCT had longer OS compared to those treated with all other regimens. WBC >11 x10 9 /L and abnormal karyotype were independent predictors of inferior survival whereas SCT was beneficial. Regimen N Age (y) ANNOVA CR Chi Sq HCT Chi Sq 1y OS mOS (mo) Log-rank Tagraxofusp 9 68 (40-70) <0.001 7 (78%) 0.548 6 (67%) 0.018 88% 20.8 0.121 ALL 13 43 (20-72) 8 (67%) 8 (62%) 74% 50.7 Hyper-CVAD 11 43 (20-72) 6 (60%) 6 (60%) 67% 35.8 AML 18 70 (48-80) 13 (76%) 5 (28%) 58% 14.2 Intensive 8 66 (48-77) 7 (88%) 3 (38%) 57% 12.4 HMA+Venetoclax 8 69 (65-80) 6 (75%) 2 (25%) 50% 14.0 Lymphoma 8 74 (49-85) 3 (43%) 1 (13%) 50% 14.0 CHOP 6 74 (49-85) 3 (50%) 1 (17%) 50% 17.7 Other 3 66 (63-73) 1 (33%) 0 (0%) 33% 12.0
Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: Analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients.
Alsugair, Ali, Mariotti, E, Alhousani, Mohammad M., Fathima, Saubia, Foran, James M. , Mangaonkar, Abhishek A. , Litzow, Mark R. , Sproat, Lisa , Palmer, Jeanne , Gangat, Naseema , Patnaik, Mrinal M. , Tefferi, Ayalew , Alhousani, Mohammad , Fathima, Saubia , Bolarinwa, Abiola , Murthy, Hemant S. , Hogan, William J. , Shah, Meera , Alkhateeb, Hassan B.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 6558-6558

10.1200/jco.2025.43.16_suppl.6558 Get It

6558 Background: Allogeneic stem cell transplantation (ASCT) is currently the only curative therapy in chronic myelomonocytic leukemia (CMML). Methods: A Mayo Clinic enterprise-wide database search identified 138 CMML cases who underwent ASCT. Conventional statistical methods were used for analyses. Results: 138 CMML patients (transplanted between 1995-2024) were included (median age 63 years; males 62%);104 (group A) received ASCT before and 34 (group B) after blast transformation (BT). At initial diagnosis, CMML-1/CMML-2 and dysplastic/proliferative representations were 78%/22% and 54%/46%; 31% displayed abnormal karyotype and most frequent mutations were ASXL1 (56%), TET2 (44%) and SRSF2 (38%). At time of initial diagnosis, CPSS-Mol risk categories were low (17%), intermediate-1 (11%), intermediate-2 (40%), and high (32%). Median time from diagnosis to ASCT was 11 months (range 0-201). Median overall survival (OS) from the time of initial diagnosis was 67 months (range 4-239) and from the time of ASCT 54 (range 0-212) months. Occurrence of BT before ASCT was associated lower post-transplant survival (PTS; 16 vs 95 months, P=0.01, HR 1.9, 95%CI 1.2-3.2). Bone marrow (BM) blasts, at the time of ASCT, <5%, 5-9%, and 10-19% correlated with median OS of 171, 81, and 18 months in group A (p=0.01) and 50, 25, and 13 months in group B (P=0.07), respectively. Pre-ASCT hypomethylating agent exposure was associated with lower PTS in group A (P=0.02). PTS was also adversely affected by DNMT3A and SETBP1 mutations. In group A, PTS was the longest with myeloablative busulfan-based (median not reached) and the shortest (median 22 months) with Cy-TBI-based conditioning (p=0.1). Donor type did not impact PTS: matched unrelated (63%), matched sibling (23%), mismatched unrelated (7%), or haplo-identical (7%). Post-transplant cyclophosphamide was associated with a numerically lower median PTS (22 months), compared to other forms of GVHD prophylaxis (107 months; p=0.1) and significantly higher non-relapse mortality (p=0.02). Documentation of morphologic CR at day 100 was associated with significantly longer PTS in both groups A (92%,164 vs. 18 months; p=0.01) and B (84%, 42 vs. 11 months; p=0.01). The presence of abnormal karyotype at day 100 was associated with shorter PTS in group A (p=0.01). Grade ≥3 acute and moderate to severe chronic GVHD occurred in 20% and 34%, respectively, in group A patients and in 26% and 44% in group B. GRFS at 1/3 years were 42/21% in group A and 31/16% in group B. At last follow up, 44% in group A and 65% in group B were dead. Causes of death were relapse/non-relapse related in 36/64% in group A and 39/61% in group B. Conclusions: ASCT is effective in securing long-term survival in CMML, especially when the procedure is performed prior to BT and in the setting of <5% BM blasts/promonocytes. Response assessment at day 100 was highly informative of outcome.
Should we treat TP53-mutated high-risk myeloid neoplasms in older patients?
Kettani, Mobachir El , Shah, Kashish, Shallis, Rory M. , Diebold, Kendall , Coltoff, Alexander , Foucar, Charles , Palmisiano, Neil , Litzow, Mark R. , Badar, Talha , Jamy, Omer , Goldberg, Aaron D. , Patel, Anand , Bewersdorf, Jan Philipp , Abaza, Yasmin , DuVall, Adam , Kota, Vamsi , Zeidan, Amer M. , Atallah, Ehab

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 6538-6538

10.1200/jco.2025.43.16_suppl.6538 Get It

6538 Background: TP53 mutated ( TP53 mt ) high-risk myeloid neoplasm (HR-MN) confers a dismal prognosis in the contemporary era with only a subset of eligible patients (pts) able to achieve long-term remission with allogeneic stem cell transplantation (allo-HCT). Owing to poor outcomes, many physicians believe it is futile to treat older pts with disease-directed therapy, since curative intent allo-HCT cannot be offered. We sought to describe the outcomes of older pts with TP53 mt HR-MN receiving disease directed treatment. Methods: We conducted a multicenter observational study in collaboration with 11 U.S. academic centers under the COMMAND consortium. We reviewed the data of 451 older (≥ 60 years [yrs]) TP53 mt HR-MN (n= 282 acute myeloid leukemia [AML], n= 91 MDS transformed AML, n= 50 myeloproliferative neoplasm blast phase (MPN-BP) and n= 28 high-risk myelodysplastic syndromes [HR-MDS]) pts to analyze their outcome with disease directed treatment. Results: The median age was 70 yrs (range [R],60-90) and 58% were male. Proportions of pts with age ≥ 70 yrs were 47.5%. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) was available in 68% (n= 306) of pts; 10.5%, 49%, 32% and 8.5% had ECOG-PS 0-3, respectively. The median bone marrow (BM) blast % was 32 (R, 5-99) and TP53 variant allele frequency (VAF) was 45% (R, 2-97). The proportion of pts with multi-hit (MH) TP53 mt and complex cytogenetics (CG) was 83% and 82%, respectively. 43 %, 31%, 20% and 6% received hypomethylating agent (HMA) + venetoclax, intensive chemotherapy, HMA and other low-intensity therapy, respectively. The complete remission rate with or without count recovery (CR/CRi) amongst evaluable patients (n= 356) was 37%. The median duration of response was 6.7 months (mo) (R, 5.9-7.5). Amongst 56 (12%) pts who underwent allo-HCT, the median overall survival (mOS) from time of allo-HCT was 21.9 mo. The mOS among pts ≥ 70 yrs was 6.5 mo. The mOS in mo was better in HR-MDS (16.4), compared to de novo AML (6.5), MDS transformed AML (7.1) and MPN-BP (5.27), p= 0.003. We conducted multivariable analysis for OS using baseline variables that were significant/ showed trend towards significance, on univariate analysis ( p <0.1). HR-MDS (HR; 0.43, 95% CI: 0.23-0.82, p= 0.01), CR/CRi (HR; 0.55, 95% CI: 0.39-0.77, p= <0.001) and allo-HCT (HR; 0.28, 95% CI: 0.16-0.47, p= <0.001) positively impacted OS. Whereas age ≥ 70 yrs showed trends towards inferior OS (HR; 1.31, 95% CI: 0.95-1.80, p=0.09). Complex CG (HR; 1.63, 95% CI: 0.83-3.21, p =0.15) and MH TP53 mut (HR; 1.30, 95% CI: 0.67-2.52, p= 0.42) did not retain significance for OS. Conclusions: Our multi-center study suggests that disease directed treatment in older TP53 mt HR-MN leads to modest response rates with short durations of response in the absence of allo-HCT. 12% of pts were able to receive allo-HCT with improvement in OS close to 2 yrs. The decision to treat this poor risk gp of pts should be based on individual pt characteristics and desires.
Comparing trends in telehealth utilization by medical oncology practices at Stanford Medicine and Mayo Clinic from 2019–2023.
Parameswaran, Vijaya , Miller, Marci, Grimm, Jessica, Gullerud, Rachel E., Fan, Winnie, Gibbons, Daniel J., Oyarzabal, Beatriz A., Lunde, Julianne J. , Rosengaus, Leah, Sharp, Christopher , Shah, Sumit , Haddad, Tufia C. , Grimm, Jessica, Coffey, Jordan , Harper, Sarah, Demaerschalk, Bart M. , Pritchett, Joshua C.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e13890 Get It

e13890 Background: Many oncology practices have reported continued use of telemedicine since onset of the COVID-19 pandemic. However, the future sustainability of telemedicine within oncology practices remains unclear, particularly because federal policies that enabled adoption in response to the public health emergency (PHE) have not been made permanent. Understanding similarities and differences in telemedicine utilization at high-volume oncology centers is crucial for shaping evidence-based policy that enables equitable access to oncology care across varying geographies. Methods: This is a cross-sectional, year-over-year, retrospective cohort analysis of trends in telemedicine utilization across all medical oncology clinical appointments conducted among adult patients (age >18) from January 2019 to December 2023 at Stanford Medicine Cancer Center (SM) – comprising multiple campuses in the California Bay Area – and the Mayo Clinic Comprehensive Cancer Center (MC) – a multiregional cancer practice with tertiary referral campuses in Minnesota, Florida, and Arizona, as well as community-based clinics throughout the Upper Midwest. Results: Both institutions exhibited a similar trend in telemedicine adoption over time. This was characterized by an initial surge in utilization following the PHE declaration in March 2020, followed by sustained utilization rates from 2021 to 2023. However, telemedicine use as a proportion of the overall practice differed significantly between institutions. At SM, the rate of telemedicine visits as a proportion of overall clinical practice was 60.3% (49,136/ 81,502) in 2021, 59.9% (52,247/ 87,215) in 2022, and 57.2% (55,007/ 96,163) in 2023. At MC, the proportion of telemedicine utilization was 12.8% in 2021 (23,873/186,086), 14.7% in 2022 (28,985/196,777), and 14.0% in 2023 (30,208/215,941). Deployment in the setting of new versus return visits also differed between institutions. In 2023, telemedicine accounted for 53.7% (6,440/11,998) of new and 57.7% (48,567/84,165) of return visits at SM, compared to 15.5% (3,359/21,728) and 13.8% (26,849/194,213) at MC. Additionally, while video visits were the predominant modality used to conduct telemedicine visits at both institutions from 2021 onward, in 2023 phone visits still made up 17.9% (5,394/30,208) of all telemedicine visits at MC, compared to just 5.4% (2,990/55,007) at SM. Conclusions: Stanford Medicine and Mayo Clinic exhibited a pattern of initial growth of telemedicine adoption in 2020, followed by sustained utilization from 2021-2023. We observed unique differences in the overall proportion, visit type deployment, and modality of telemedicine utilization between institutions. However, this study confirms telemedicine visits have remained a fixture of medical oncology care for many patients at these institutions since the COVID-19 pandemic.
TP53 multihit mutations in 142 patients with MPN or AML: Comparative analysis of survival and risk factors.
Abdelmagid, Maymona, Alsugair, Ali, Mangaonkar, Abhishek A. , Pardanani, Animesh , Patnaik, Mrinal M. , Zepeda‐Mendoza, Cinthya , He, Rong , Reichard, Kaaren K. , Foran, James M. , Gangat, Naseema , Tefferi, Ayalew , Fathima, Saubia , Badar, Talha , Loscocco, Giuseppe Gaetano , Guglielmelli, Paola , Vannucchi, Alessandro M. , Orazi, Attilio , Arber, Daniel A. , Hiwase, Devendra , Shah, Meera

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e18590 Get It

e18590 Background: TP53 mutations ( TP53 MUT ) are known to be associated with adverse prognosis in acute myeloid leukemia (AML) and multihit TP53 MUT in myelodysplastic syndromes (MDS). The prognostic relevance of multihit TP53 MUT in myeloproliferative neoplasms (MPN) was recently highlighted. The current study illustrates survival comparisons in multihit TP53- mutated MPN vs. AML and analysis of associated risk factors. Methods: A Mayo Clinic enterprise-wide database search identified 61 MPN and 81 AML cases with multihit TP53 MUT . Conventional statistical methods were used for analyses. Results: 142 patients with multihit TP53 MUT were included: i) chronic phase MPN (MPN-CP; N=19), ii) accelerated phase MPN (MPN-AP; N=14), iii) blast phase MPN (MPN-BP; N=28) and iv) AML, not including MPN-BP (N=81). Concomitant ASXL1 MUT , EZH2 MUT , IDH1 MUT and IDH2 MUT were more common in MPN-BP, compared to AML. At a median follow up of 0.6 years, 124 (87%) deaths and 19 (13%) allogeneic stem cell transplantations (ASCT) were documented. Overall survival (OS), calculated from time of TP53 MUT detection was similar between MPN-BP (median 4.6 months) and MPN-AP (5.6 months; p=0.5). OS in MPN-BP/AP (median 4.8 months) was inferior to that of AML (median 7.4 months; p=0.04) while that of MPN-CP (median 11.6 months) was similar to AML (0.07) but superior to that of MPN-BP/AP (p<0.01). Age-adjusted multivariable analysis (MVA) confirmed the independent prognostic significance of undergoing ASCT (HR 0.4, p=0.03), MPN-CP or achieving response to pre-transplant therapy (HR 0.2, p<0.01), and concurrent TET2 MUT or DNMT3A MUT (HR 2.7, p<0.01) on OS. Based on these risk factors, a 3-tiered risk model was constructed: low (no risk factors; N=18; median OS 23.8 months); intermediate (1 risk factor; N=44; median 11.1 months); and high (2 or more risk factors; N=80; median 4 months; p<0.01). Comparative analysis of risk factors among distinct diseases confirmed the prognostic significance of ASCT (HR 0.3, p=0.03), achieving response to pre-transplant therapy (0.4, p<0.01) and concurrent TET2 MUT or DNMT3A MUT (HR 5.0, p<0.01) in AML. In MPN AP/BP, OS was influenced by having received chemotherapy vs. supportive care (HR 0.1; p<0.01) and achieving response to pre-transplant therapy (0.2, p<0.01). No significant risk factors for OS were identified in MPN-CP. In MVA, ASCT did not appear to influence OS in MPN AP/BP (p=0.7) and MPN-CP (p=0.4) but the number of informative cases was too low to make definitive conclusions. Conclusions: The current study highlights the equally detrimental impact of multihit TP53 MUT in securing long-term survival in MPN and AML. Short-term survival was positively influenced by ASCT, at least in AML, and disease stage or remission status at time of mutation detection and ASCT, respectively.
Impact of telemedicine on access to care in surgical oncology clinics: Distance and time to visit analysis for new patients at a multispecialty cancer center.
Parameswaran, Vijaya , Tsung, Sean, Miller, M. , Rosengaus, Leah, Sharp, Christopher , Lee, Byrne , Shah, Sumit , Zeng, Yan Bo, Pritchett, Joshua C. , Demaerschalk, Bart M.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e23345 Get It

e23345 Background: Telemedicine enables patients to attend visits remotely and is associated with shorter wait times (i.e. scheduling-to-appointment duration). However, its impact on patient–clinic distance and wait times for new patients in high-volume surgical oncology centers remains unclear. In these centers, where appointment availability and travel distance significantly influence care decisions, understanding telemedicine’s impact on access is essential as federal policies supporting telemedicine continue to be under legislative review. To address this, we examined the relationship between new patient visit modality, distance, and wait time across demographics, providing insights to guide policy makers, and clinical practice. Methods: We extracted visit data from a multispecialty surgical oncology center in Northern California from 2019 to 2023 and used linear models with fixed effects for clinician and patient characteristics to assess the association of NPV modality with distance and wait times. We calculated distance using geodesic measurements between residential ZIP codes and care sites and derived median household income and education levels from the American Community Survey. Results: There were 10596 NPVs in 2019, and 13982 in 2023, conducted by 78 and 100 clinicians respectively. The proportion of NPV visits conducted by telemedicine increased from 0% to 28% during this period. From 2021–2023, NPVs conducted by telemedicine were more likely to fall outside the center’s 2019 catchment area (80th percentile of distance) with an adjusted odds ratio of 1.89 (95% CI 1.62, 2.21). Wait times for telemedicine NPVs was 3.0 days shorter (95% CI [2.0, 3.9]) than in-person visits. Compared to the reduction in wait times for patients aged 45–65 (2.8 days, 95% CI [1.8, 3.8]), those 80 and older had a smaller reduction (1.9 days, 95% CI [0.9, 2.8]), while patients aged 65–79 had a greater reduction (3.4 days, 95% CI [2.4, 4.5]). This effect did not significantly vary by sex, race, ethnicity, education, income, or insurance status. Conclusions: At this multispecialty surgical oncology center, new patients seen via telemedicine were more likely to reside outside the center’s traditional catchment area and had shorter wait times, with these differences varying by demographic characteristics. Strategic telemedicine integration tailored to patient needs could enhance access by reducing wait times and expanding specialized surgical oncology care to patients across broader geographic distances.